Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. The company was founded in 2005 and is headquartered in Englewood, Colorado.
IPO Year:
Exchange: NASDAQ
Website: viveve.com
SC 13G/A - VIVEVE MEDICAL, INC. (0000879682) (Subject)
SC 13G/A - VIVEVE MEDICAL, INC. (0000879682) (Subject)
SC 13G/A - VIVEVE MEDICAL, INC. (0000879682) (Subject)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
Alliance Global Partners initiated coverage of Viveve Medical with a rating of Buy
Alliance Global Partners initiated coverage of Viveve Medical with a rating of Buy and set a new price target of $10.75
Study's primary efficacy endpoint was not achieved at 12 months post-treatmentCompany has implemented a reduction in forceCompany will seek strategic alternatives and will be delisted from Nasdaq ENGLEWOOD, CO / ACCESSWIRE / January 17, 2023 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced topline result from the U.S. Pivotal PURSUIT clinical trial. PURSUIT was a multicenter, randomized, double-blinded, sham-controlled U.S. study to evaluate the safety and efficacy of the Viveve treatment for SUI in women. The results were obtained by the company on Friday evening, Janu
Topline results of the 12-month primary efficacy endpoint anticipated in January 2023Positive results may support a de novo marketing application for a new U.S. indication for treatment of stress urinary incontinence in womenENGLEWOOD, CO / ACCESSWIRE / December 15, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and treatment of female stress urinary incontinence, today announced the completion of final 12-month post-treatment follow-up visits in its landmark U.S. PURSUIT clinical trial for the treatment of stress urinary incontinence (SUI) in women. A total of 415 patients were enrolled in the trial, and 342 patients completed 12-month foll
Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT clinical trialENGLEWOOD, CO / ACCESSWIRE / December 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11511110 covering Viveve's treatment to address SUI in women. The issuance of the new patent strengthens the Company's intellectual property portfolio in advance of the planned completion of its U.S. pivotal PURSUIT clinical trial by the e
Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tipsPURSUIT clinical trial completion expected by year-endConference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / November 10, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today reported financial results for the quarter ended September 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the third quarter of 2022, we continued to make great progress in the final phase of our pivotal U.S. PURSUIT clinical trial fo
ENGLEWOOD, CO / ACCESSWIRE / October 27, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its third quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 10, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The third quarter 2022 results conference call may be accessed on Thursday, November 10th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://event.choruscall.com/mediaframe/we
Patent issuance further strengthens Viveve's intellectual property portfolio for the treatment of female stress urinary incontinenceENGLEWOOD, CO / ACCESSWIRE / October 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application 16/454,578 covering Viveve's unique dual-energy treatment to address SUI in women. The pending issuance of the new SUI patent further strengthens the Company's intellectual property portfolio in advance of the planned com
New branding reflects Company's vision to be the leader in the treatment of Stress Urinary Incontinence in WomenCompletion of PURSUIT follow-up visits anticipated by the end of 2022 with topline results expected shortly thereafterENGLEWOOD, CO / ACCESSWIRE / September 27, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced the launch of a company-wide rebranding initiative that will include content and new graphic elements related to the treatment of SUI in women. The rebranding is being completed in advance of the planned reporting of topline results from Viveve's piv
ENGLEWOOD, CO / ACCESSWIRE / September 22, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg Thalmann Healthcare Conference, September 29, 2022, in New York City. Mr. Durbin will deliver the Viveve corporate presentation and provide an update on progress of the Company's SUI clinical development program. He will also meet with investment community members during the conference.Event: Ladenburg Thalmann Healthcare ConferenceThursday, September 29, 2022Webcast: Thursday, September 29th, 8:30 AM ETTh
ENGLEWOOD, CO / ACCESSWIRE / September 15, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Alliance Global Partners Virtual MedTech Conference, September 21, 2022. Mr. Durbin will provide an update on Viveve's operations including progress of its SUI clinical development program and will meet with investment community members during the virtual conference.Event:Alliance Global Partners Virtual MedTech ConferenceWednesday, September 21, 2022About ViveveViveve Medical, Inc. is a medical technology company f
ENGLEWOOD, CO / ACCESSWIRE / September 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12 - 14, 2022. Mr. Durbin will deliver the Viveve corporate presentation and meet with investment community members during the hybrid conference.Event: H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 12 - 14, 2022Presentation Webcast: Monday, September 12, 2022, 7:00 AM ETThe corporate presentation will be webcast on the Investors s
15-12G - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
S-8 POS - VIVEVE MEDICAL, INC. (0000879682) (Filer)
POS AM - VIVEVE MEDICAL, INC. (0000879682) (Filer)
Gainers Ontrak (NASDAQ:OTRK) stock increased by 44.3% to $0.83 during Wednesday's pre-market session. The market value of their outstanding shares is at $22.4 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 25.55% to $6.19. The market value of their outstanding shares is at $246.0 million. Tricida (NASDAQ:TCDA) stock moved upwards by 21.81% to $0.16. The market value of their outstanding shares is at $9.3 million. Avenue Therapeutics (NASDAQ:ATXI) stock increased by 18.59% to $2.36. The market value of their outstanding shares is at $11.2 million. Sigilon Therapeutics (NASDAQ:SGTX) shares moved upwards by 14.89% to $0.47. The market value of their outstanding shares
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Tuesday. The Dow traded down 0.87% to 34,003.26 while the NASDAQ rose 0.25% to 11,106.50. The S&P 500 also rose, gaining, 0.01% to 3,999.18. Check This Out: Global Crypto Market Cap Hits $1 Trillion; Gala, Casper Among Top Gainers Leading and Lagging Sectors Energy shares gained by 0.3% on Tuesday. Meanwhile, top gainers in the sector included HighPeak Energy, Inc. (NASDAQ:HPK), up 9%, and Vertex Energy, Inc. (NASDAQ:VTNR), up 8%. In trading on Tuesday, communication services shares fell by 1.3%. Top Headline Morgan Stanley reported better-than-expected Q4 results. Morgan Stanl
Gainers Celyad Oncology SA (NASDAQ:CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program CYAD-211. Calyxt, Inc. (NASDAQ:CLXT) gained 116% to $0.4014 after the company and Cibus announced a definitive merger agreement. BIT Mining Limited (NYSE:BTCM) shares climbed 34.5% to $4.13 after the company announced the launch of a new energy efficient LiteCoin/DogeCoin Miner, LD3. Aligos Therapeutics, Inc. (NASDAQ:ALGS) jumped 29.9% to $2.13 after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $3 to $7. Neovasc Inc. (NASDAQ:NVCN) surged 29.5% to
Gainers Celyad Oncology (NASDAQ:CYAD) stock moved upwards by 150.2% to $2.0 during Tuesday's regular session. Trading volume for Celyad Oncology's stock is 50.4 million as of 12:30 EST. This is 563061.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $45.1 million. Calyxt (NASDAQ:CLXT) shares increased by 109.47% to $0.39. The current volume of 66.6 million shares is 16560.9% of Calyxt's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $18.9 million. Theseus Pharmaceuticals (NASDAQ:THRX) stock moved upwards by 27.4% to $12.23. As of 12:30 EST, this security is trading a
Tuesday saw 9 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Embecta (NASDAQ:EMBC) is the largest company in terms of market cap to set a new 52-week low this morning. The smallest company on a market cap basis to set a new 52-week low was Viveve Medical (NASDAQ:VIVE). Viveve Medical (NASDAQ:VIVE) shares traded down 70.38% to reach its 52-week low, making it the biggest loser. Embecta (NASDAQ:EMBC) was the most promising stock of the group, with shares actually trading up 1.6% to bounce back after reaching its new 52-week low. The stocks that set new 52-week lows on Tuesday: Embecta (NASDAQ:EMBC) shares reached a new 52-week low of $22.30 on
U.S. stocks traded mostly lower midway through trading, with the Dow Jones dropping over 300 points on Tuesday. The Dow traded down 0.95% to 33,977.92 while the NASDAQ fell 0.06% to 11,072.64. The S&P 500 also fell, dropping, 0.10% to 3,995.27. Check This Out: Global Crypto Market Cap Hits $1 Trillion; Gala, Casper Among Top Gainers Leading and Lagging Sectors Energy shares gained by 0.5% on Tuesday. Meanwhile, top gainers in the sector included HighPeak Energy, Inc. (NASDAQ:HPK), up 8%, and Vertex Energy, Inc. (NASDAQ:VTNR), up 9%. In trading on Tuesday, communication services shares fell by 1%. Top Headline Morgan Stanley reported better-than-expected Q4 results. Morgan
Gainers Calyxt (NASDAQ:CLXT) stock increased by 140.3% to $0.45 during Tuesday's pre-market session. The company's market cap stands at $21.7 million. Celyad Oncology (NASDAQ:CYAD) shares increased by 117.77% to $1.74. The company's market cap stands at $39.3 million. Vallon Pharmaceuticals (NASDAQ:VLON) shares moved upwards by 17.62% to $0.32. The company's market cap stands at $4.3 million. Cardio Diagnostics Hldgs (NASDAQ:CDIO) shares moved upwards by 17.18% to $1.5. The company's market cap stands at $14.2 million. Immuron (NASDAQ:IMRN) shares moved upwards by 14.99% to $2.3. The market value of their outstanding shares is at $13.0 million. Leap Therapeutics (NASDAQ:LPTX) stock ros
Viveve Medical Inc (NASDAQ:VIVE) announced topline results from the U.S. Pivotal PURSUIT clinical trial evaluating Viveve treatment for stress urinary incontinence (SUI) in women. The study did not meet its primary endpoint of achieving a statistically significant higher proportion of patients experiencing more than a 50% reduction in urine leakage compared to baseline on the standardized 1-hour Pad Weight Test at 12 months post-treatment in the active treatment versus the sham control group. About 415 subjects participated in the trial. 49.8% of patients reported over a 50% reduction in leakage in the active group and 56.7% in the sham group. The study also did not meet several secon
Viveve Medical, Inc. (NASDAQ:VIVE) today announced topline result from the U.S. Pivotal PURSUIT clinical trial. PURSUIT was a multicenter, randomized, double-blinded, sham-controlled U.S. study to evaluate the safety and efficacy of the Viveve treatment for SUI in women. The results were obtained by the company on Friday evening, January 13, 2023. The PURSUIT study did not meet its primary endpoint of achieving a statistically significant higher proportion of patients who experienced greater than a 50% reduction in urine leakage compared to baseline on the standardized 1-hour Pad Weight Test at 12 months post-treatment in the active treatment group versus the sham control group. The analysi
Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tipsPURSUIT clinical trial completion expected by year-endConference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / November 10, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today reported financial results for the quarter ended September 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the third quarter of 2022, we continued to make great progress in the final phase of our pivotal U.S. PURSUIT clinical trial fo
ENGLEWOOD, CO / ACCESSWIRE / October 27, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its third quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 10, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The third quarter 2022 results conference call may be accessed on Thursday, November 10th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://event.choruscall.com/mediaframe/we
Total revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tipsPURSUIT clinical trial follow-up visit completion anticipated by year endConference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / August 11, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today reported financial results for the quarter ended June 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the second quarter of 2022, we continued to advance our stress urinary incontinence (SUI) clinical development program. We
ENGLEWOOD, CO / ACCESSWIRE / July 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its second quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, August 11, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The second quarter 2022 results conference call may be accessed on Thursday, August 11th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://event.choruscall.com/mediaframe/webcast
Total revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tipsPURSUIT trial top-line results anticipated at end of 2022Conference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / May 12, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended March 31, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the first quarter of 2022, we continued the focus on advancing our stress urinary incontinence (SUI) clinical development program. We remain on track to complete all patient follow-up vi
ENGLEWOOD, CO / ACCESSWIRE / April 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, May 12, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day. The first quarter 2022 results conference call may be accessed on Thursday, May 12th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://services.choruscall.com/mediaframe/webcast.html?webcastid=kTDfnY3F. Participants may also
Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growthEnrollment completed in U.S. pivotal PURSUIT trial for stress urinary incontinence and 12-month post treatment follow-up visits underwayPURSUIT top-line results anticipated at end of 2022Conference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / March 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the year ended December 31, 2021. The Company will provide a corporate update on its scheduled conference call at 5:00 PM ET today."I am extremely pleased with the milestones
ENGLEWOOD, CO / ACCESSWIRE / March 3, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its full year 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, March 17, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The full year 2021 results conference call may be accessed on Thursday, March 17th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://services.choruscall.com/mediaframe/webcast.html?webcastid=NZykfofx. Participants may also registe
Total revenue of $1.6M reported for Q3Pivotal SUI PURSUIT trial enrollment nears completion - randomizations on-track for completion in Q4ENGLEWOOD, CO / ACCESSWIRE / November 11, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended September 30, 2021, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today. The Company's 10-Q documents will be filed on Friday, November 12, 2021, when the U.S. Securities and Exchange Commission reopens following the Veterans Day holiday."During the third quarter of 2021, we continued to make great progress in advancin
ENGLEWOOD, CO / ACCESSWIRE / November 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third quarter 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 11, 2021. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The Company's 10-Q documents will be filed on Friday, November 12, 2021, when the U.S. Securities and Exchange Commission reopens following the Veterans Day holiday.The third quarter 2021 results conference call may be accessed on Thursday, November 11th at 5:00 PM ET by dialing 1-833-